Background:
Peripheral artery disease (PAD) is a progressive atherosclerotic condition associated with high cardiovascular and limb-related morbidity. Despite guideline-recommended antiplatelet therapy, patients with PAD remain at substantial residual risk of ischemic and limb events. Rivaroxaban, a direct Factor Xa...
M. Shahzaib, Muhammad Roshaan, Anza Muhammad et al.· Circulation· 0 citations
Background:
Resistant hypertension (RH) is associated with increased cardiovascular morbidity and mortality, with limited treatment options due to adverse effects and suboptimal control. Aldosterone plays a central role in RH pathophysiology, making aldosterone synthase inhibition a promising therapeutic target. Bax...
M. Shahzaib, Anza Muhammad, Hafsa Ali et al.· Circulation· 0 citations
Background:
Despite advances in reperfusion therapies, acute stroke remains a leading cause of death and disability worldwide. Minocycline has emerged as a potential neuroprotective agent due to its anti-inflammatory, anti-apoptotic, and blood-brain barrier-stabilizing properties. However, randomized trials have rep...
M. Shahzaib, Anza Muhammad, Muhammad Roshaan et al.· Circulation· 0 citations
Baxdrostat 1 mg and 2 mg significantly increased overall adverse events and hyperkalemia, whereas serious adverse events were not significantly increased, and both higher doses significantly increased hyperkalemia risk.
M. Shahzaib, Hafsa Ali, Muhammad Roshaan et al.· Naunyn-Schmiedeberg's Archiv...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.